An Open Label, Single-Center, Pilot Trial of the Combination of Tagraxofusp TAG with Pacritinib PAC in Patients with Intermediate-1 or Higher Myelofibrosis MF, Who Have had Prior Therapy with the Approved JAK1/2 Inhibitors or in Which Therapy with the Approved JAK1/2 Inhibitors is Not Appropriate, Contraindicated or Declined by the Subjects

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
Feasibility/Pilot

ClinicalTrials.gov Identifier:
NCT00000000

Study #:
STUDY00160238

Start Date:
May 17, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT00000000

View Complete Trial Details & Eligibility at ClinicalTrials.gov